Compare SHMD & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHMD | ADAG |
|---|---|---|
| Founded | 1864 | 2011 |
| Country | Germany | China |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.3M | 84.8M |
| IPO Year | N/A | 2021 |
| Metric | SHMD | ADAG |
|---|---|---|
| Price | $4.93 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 171.3K | 73.7K |
| Earning Date | 01-01-0001 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $85,165,542.00 | $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | N/A | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.86 | $1.30 |
| 52 Week High | $6.70 | $3.16 |
| Indicator | SHMD | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 53.46 | 49.37 |
| Support Level | $3.87 | $1.76 |
| Resistance Level | $5.40 | $1.90 |
| Average True Range (ATR) | 0.66 | 0.15 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 66.88 | 53.19 |
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.